Table 3.
Chemotherapy treatment by patient group and 21-gene test Recurrence Score, Kaiser Permanente Northern California, Sept 2005 – June 2012a
| Characteristic | Total patients | Percent (n) of patients receiving chemotherapy |
|---|---|---|
| All patients | 7,004 | 23 (1,600) |
| Patients who did not have Oncotype DX testing | 5,437 | 22 (1,190) |
| Patients who had Oncotype DX testing | 1,567 | 26 (410) |
| By Recurrence Scoreb | ||
| Low risk (RS<=18) | 820 | 8 (68) |
| Intermediate risk (RS 18 to <31) | 606 | 40 (241) |
| High Risk (RS 31+) | 141 | 72 (101) |
a
Among breast cancer cases meeting National Comprehensive Cancer Network criteria for consideration of the 21-gene test (Oncotype DX). See text for inclusion criteria.
b
Differences in the percent of patients receiving chemotherapy among the three Recurrence Score groups was statistically different at p<=01.